{
    "Trade/Device Name(s)": [
        "AllTest Fentanyl Rapid Test (Urine)"
    ],
    "Submitter Information": "Hangzhou AllTest Biotech Co., Ltd.",
    "510(k) Number": "K231698",
    "Predicate Device Reference 510(k) Number(s)": [
        "K220046"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "June 11, 2023",
    "Summary Letter Received Date": "June 12, 2023",
    "Submission Date": "June 11, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Fentanyl"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunoassay",
        "Lateral flow immunochromatographic assay",
        "Competitive binding"
    ],
    "Methodologies": [
        "Immunochromatography",
        "Antigen-antibody immunochemistry"
    ],
    "Submission Type(s)": [
        "Test",
        "Cassette"
    ],
    "Document Summary": "FDA 510(k) summary for AllTest Fentanyl Rapid Test (Urine), a qualitative competitive immunoassay for fentanyl detection in human urine",
    "Indications for Use Summary": "Qualitative detection of fentanyl in human urine at 1.0 ng/mL cutoff for prescription use; provides preliminary results, confirmatory testing by GC/MS or LC/MS recommended",
    "fda_folder": "Toxicology"
}